Sanofi Garners Highest Physician Interest in Asthma Pipeline, Despite GSK’s Later-Stage Asset, According to Spherix Global Insights
Following a period of stability in the US biologic asthma market, new data reveals hidden opportunities for differentiation and growing prescriber interest in emerging pipeline therapies Exton, PA, May 13, 2025 – Although no new biologics for asthma have been approved since the 2021 launch of Tezspire (Amgen/AstraZeneca), recent insights from Spherix Global Insights point […]
Johnson & Johnson’s Oral IL-23, Icotrokinra, Poised to Redefine the Psoriasis Treatment Landscape Following Positive Phase 3 Data, According to Spherix Global Insights
Perceived first-line utility, patient pool expansion, and paradigm-shifting potential distinguish Icotrokinra in the eyes of US dermatologists EXTON, PA, April 14, 2025 – Johnson & Johnson’s recent announcement of positive Phase 3 data for its oral IL-23 receptor antagonist, icotrokinra (JNJ-2113), has sparked notable enthusiasm across the dermatology community. According to the company’s recent release, […]
A Glimpse Inside the CLE Pipeline: What’s Coming Down the Pike?
Dermatologists rely heavily on topical therapies for cutaneous lupus erythematosus (CLE), but are increasingly interested in systemic agents with user-friendly formulations and dermatology-relevant experience such as deucravacitinib (Sotyktu BMS), an oral TYK2 inhibitor currently approved for psoriasis. Familiarity with its mechanism and a favorable safety profile have positioned deucravacitinib as a top contender for future […]
Timely Findings Highlight Increased US Physician Familiarity with IRA Changes Amid Ongoing Reimbursement and Education Concerns, According to Spherix Global Insights
Recently released research reveals key insights into physician perspectives, practice management changes, and expected prescribing changes resulting from recent IRA-driven Medicare changes. EXTON, PA., April 10, 2025 — In 2025, the Inflation Reduction Act (IRA) introduced significant Medicare reforms designed to reduce financial burdens for patients, including a new cap on out-of-pocket (OOP) prescription drug […]
Humira Biosimilars Gain Ground as Doctors Adjust and New Therapies Rise
AbbVie’s Humira was the top-selling drug in the world for many years. Now, its sales are eroding as doctors switch to biosimilars and new options enter the market. Immunology physicians are starting to adjust to the new treatment paradigm brought on by the entry of Humira biosimilars, sending sales of AbbVie’s mega-blockbuster down precipitously. But the […]
BMS’ Sotyktu Notches Phase III Win in Psoriatic Arthritis
In the plaque psoriasis arena, Sotyktu is facing off against Amgen’s Otezla and is facing the threat of upcoming competition from Alumis’ investigational TYK2 inhibitor. Bristol Myers Squibb is building up to a label expansion for Sotyktu, with positive late-stage results from the POETYK PsA-2 study pointing to the potential of its TYK2 inhibitor in psoriatic arthritis. 54.2% […]
Inflation Reduction Act Likely to Shape Specialty Prescribing Decisions in 2025, According to Spherix Global Insights
Spherix Global Insights Announces New Study on Impact of Inflation Reduction Act (IRA) on Specialty Practices and Key Insights for Biopharmaceutical Companies in 2025. Exton, PA., December 10, 2024 – In 2022, the U.S. Congress enacted the Inflation Reduction Act (IRA), a landmark piece of legislation aimed at addressing various national priorities, including the reduction […]
Humira, Cosentyx gaining favor as treatments for hidradenitis suppurativa, but more support for biologics needed: Spherix
The introduction of biologic therapies for hidradenitis suppurativa (HS) has “revolutionized” treatment for the rare inflammatory skin condition, though there’s still plenty of progress to be made, according to Spherix Global Insights. A new white paper from the market research firm charts the impact of the introduction of biologics as a treatment for HS. First to earn […]
Spherix Global Insights Focuses on Earlier use of Advanced Treatments in Hidradenitis Suppurativa (HS) as a Catalyst for Better Patient Outcomes
Spherix Global Insights’ White Paper Highlights MarketExpansion and Strategies for Opportunities in HS. Exton, PA, November 7, 2024 — Spherix Global Insights has published a new white paper, Earlier Diagnosis and Treatment: The Key to Better Outcomes in Hidradenitis Suppurativa, underscoring how early intervention with advanced therapies can significantly enhance patient outcomes in Hidradenitis Suppurativa […]
Shifts in the Psoriasis Market Suggest Strong Potential for Emerging Oral Therapies
With the potential rise of new oral agents, dermatologists are increasingly optimistic about safer, more convenienttreatment options for psoriasis, according to Spherix Global Insights. Exton, PA, October 16, 2024 – Biologics have long been the cornerstone of psoriasis (PsO) treatment, valued for their proven efficacy and safety. However, the growing demand for convenient, less invasive […]
